90y-epratuzumab tetraxetan
mAbexperimentalADC
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01101581)
Timeline
Indications
Mechanism of action
- CD22Radiodepletion
CD22 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- 90y-epratuzumab tetraxetan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02844530 | Phase 2 | Nov 13, 2015 | University of Nantes |
| NCT01147393 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Cornell University, Immunomedics |
| NCT01101581 | Phase 1/Phase 2 (Phase 2) | May 1, 2010 | Immunomedics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunomedics | For profit | 2 | 1 | 1 | 2010 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1